// App-Quantinova.ai

5051 : Indirect treatment comparison of the efficacy of olaparib 300 mg tablets BID and cabazitaxel 25 mg/m2 every 3 weeks plus daily prednisolone and granulocyte colony-stimulating factor in the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC).

Researchers

Presenter

  • Tim Reason

Principal Investigators

  • Charles McCrea

  • Robert Hettle

  • Sameer Ghate

  • Christian Heinrich Poehlein

  • David Olmos

Medical Centers

  • Estima Scientific, London, United Kingdom

  • Merck & Co., Inc., Kenilworth, NJ, Centro Nacional de Investigaciones Oncológicas, Madrid, Spain

Locations

  • United Kingdom

  • Spain

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Urology

Disease

  • Metastatic castration-resistant prostate cancer

Biomarkers

  • Breast cancer type 1 susceptibility protein

  • Ataxia-telangiectasia mutated

Drug/Treatment

  • Prednisolone

  • Cabazitaxel

  • Olaparib

  • taxane

Outcome

  • N/A

Study Design

  • N/A

Phase

  • IV

Study Id's

  • NCT02987543

  • NCT02485691

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved